NIH unit grants XOMA $65M to work on botulism treatment

09/10/2008 | American City Business Journals

The National Institute of Allergy and Infectious Diseases awarded XOMA a $65 million contract to develop a treatment for botulism, a potentially lethal disease caused by a neurotoxin from the bacterium Clostridium botulinum. XOMA intends to begin trials next year for its first antibody product against the disease.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT